Table 1.
Mean reduction in reported cases, hospitalization, and reported deaths or mortality from equal-sized HVIs by targeted age group, assuming maximal 15% efficacy for both transmission reduction and clinical effectiveness
| HVI initiation month | 20+ | 40+ | 65+ | ||||||
| Reported cases | Hospitalization | Mortality | Reported cases | Hospitalization | Mortality | Reported cases | Hospitalization | Mortality | |
| September | 24.1 | 7.9 | 7.3 | 18.9 | 10.9 | 12.7 | 6.8 | 9.1 | 13.3 |
| October | 24.3 | 9.0 | 8.4 | 18.9 | 11.3 | 12.4 | 6.8 | 9.0 | 13.1 |
| November | 24.5 | 12.1 | 11.8 | 18.8 | 12.8 | 14.1 | 6.7 | 9.1 | 13.2 |
| December | 22.6 | 16.0 | 16.4 | 17.0 | 14.2 | 15.7 | 6.0 | 8.7 | 12.5 |
| January | 15.7 | 14.4 | 14.9 | 11.9 | 12.2 | 13.5 | 4.5 | 7.4 | 10.7 |
| February | 6.7 | 7.0 | 7.4 | 5.4 | 6.3 | 7.0 | 2.3 | 4.0 | 5.7 |
Percent reduction versus baseline simulation through June 30th, 2021; maximal reduction in each category in bold.